Loading data for NUVB — first visit, this takes a few seconds.
Nuvation Bio Inc. (NUVB)
NYSE: NUVB
· Real-Time Price · USD
6.07
-0.21 (-3.34%)
At close: Sep 11, 2026, 3:59 PM
5.95
-1.98%
After-hours: 6:26 PM
The price, the headline numbers and the latest news, in one place.
Nuvation Bio Inc. (NUVB) Stock Price, Analysis & Data
-3.34% (1D)
| Bid | 6.16 |
| Market Cap | 2.13B |
| Revenue (ttm) | 170M |
| Net Income (ttm) | -150M |
| 1.53 | |
| -0.44 | |
| n/a | |
| -404.67 | |
| P/B (ttm) | 8.36 |
| P/S (ttm) | 12.54 |
| Earnings Date | Nov 2, 2026 |
| Ask | 6.15 |
| Volume | 4,317,951 |
| Avg. Volume (20D) | 6,759,226 |
| Open | 6.36 |
| Previous Close | 6.28 |
| Day's Range | 5.95 - 6.39 |
| 52-Week Range | 2.99 - 9.75 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 2020
Employees 305
Stock Exchange NYSE
Ticker Symbol NUVB
Website https://www.nuvationbio.com
Financial Performance
In 2025, Nuvation Bio's revenue was 62.9M, an increase of 698.96% compared to the previous year's 7.87M. Earnings were -204.63M, a decrease of -63.97%.
Financial StatementsEarnings Surprise
Nuvation Bio has released their quarterly earnings on Aug 6, 2026:
- Revenue of $31.69M misses estimates by $0, with 555.64% YoY growth.
- EPS of -0.15 misses estimates by -0.03, with -7.14% YoY decline.
Nuvation Bio Inc. is scheduled to release its earnings on Nov 2, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2